Isoleucine Translase (IARS2) as A Drug Target and Biomarker (G55699)

Target Name: IARS2

NCBI ID: G55699

IARS2

Isoleucine Translase (IARS2) as A Drug Target and Biomarker

Isoleucine translase (IARS2) is a enzyme that plays a crucial role in the metabolism of the amino acid isoleucine. It is an essential enzyme that is involved in the breakdown of isoleucine into its amino acid precursors, such as alanine and glutamine. IARS2 is also involved in the regulation of amino acid levels in the body, which is important for maintaining cellular homeostasis and for the development and maintenance of tissues.

IARS2 is a protein that is expressed in a variety of tissues throughout the body, including the brain, heart, kidneys, and liver. It is primarily localized to the cytoplasm of cells, where it is involved in the metabolism of isoleucine. IARS2 is a monomeric protein that consists of 255 amino acids. It has a molecular weight of 31.1 kDa and a pI of 6.9.

IARS2 is involved in the breakdown of isoleucine into its amino acid precursors. Isoleucine is a non-essential amino acid that can be synthesized in the body, but it is also obtained from dietary sources such as protein-rich foods. It is important for the growth and development of tissues, as well as for maintaining cellular homeostasis. IARS2 is involved in the breakdown of isoleucine into its precursors, which allows it to be recycled and reused in the body.

IARS2 is also involved in the regulation of amino acid levels in the body. Amino acids are essential nutrients that are required for the development and maintenance of tissues, and they play a crucial role in the regulation of various cellular processes. The levels of amino acids in the body must be carefully maintained in order to ensure that cells can function properly and that they can repair damaged tissue. IARS2 is involved in the regulation of amino acid levels by breaking down the amino acid precursors and by promoting the recycling of amino acids that have been synthesized but are no longer needed.

In addition to its role in the regulation of amino acid levels, IARS2 is also involved in the development and maintenance of tissues. The breakdown of isoleucine into its amino acid precursors allows it to be used as a source of nitrogen, which is essential for the growth and development of tissues. IARS2 is also involved in the regulation of cellular signaling, as it is often targeted by signaling pathways that regulate cellular processes such as cell division and differentiation.

IARS2 is a drug target (or biomarker) that can be targeted by small molecules or antibodies to inhibit its activity. The inhibition of IARS2 has been shown to have a variety of therapeutic effects, including the inhibition of cancer cell growth and the regulation of cellular signaling pathways. Additionally, the activation of IARS2 has been shown to have a variety of diagnostic potential, including as a biomarker for certain diseases.

In conclusion, Isoleucine translase (IARS2) is an essential enzyme that is involved in the breakdown of isoleucine into its amino acid precursors, as well as the regulation of amino acid levels and the development and maintenance of tissues. Its inhibition has been shown to have a variety of therapeutic and diagnostic effects, making it an attractive target for small molecules and antibodies. Further research is needed to fully understand the role of IARS2 in the body and its potential as a drug target.

Protein Name: Isoleucyl-tRNA Synthetase 2, Mitochondrial

The "IARS2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IARS2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets